Objective: Constructed the recombinant HSV-1 deleted ICP47 and inserted human IL-12, and investigate the virus' replication ability and oncolytic property in vitro and vivo. Methods: The recombinant HSV-1 deleting ICP47 (MH1005) and then inserting human IL-12 (MH1006) were obtained with bacterial artificial chromosome technology.The replication ability and the efficiency of inhibiting tumor were detected in several nerve tumor cell lines infected with HSV-wt, MH1005 and MH1006 respectively.The murine tumor model was established by subcutaneous inoculation Neuro-2a cells on both sides of mice back respectively.A dosage of 2×10(6) PFU of HSV-wt, MH1001(recombinant HSV-1 deleted IR), MH1005, MH1006 and Mock were injected 3 times intratumorally on one side of mice back in every 3 days, the tumor volume and survival rate of the mice were measured. Results: The replication abilities of MH1005, MH1006 and HSV-wt in 293FT cells were insignificant (P>0.05); the replication abilities of recombinant HSV-1 in G422 and Neuro-2a were higher than that in SK-N-SH; and the nerve tumor cells could be inhibited significantly by recombinant HSV-1.After 15 days of treatment, on the mouse backside with injection treatment, the tumor volumes of group HSV-wt (6 267±484), MH1001 (5 730±1 071), MH1005 (4 537±538)and MH1006 (4 150±476)mm(3) were smaller than that of group Mock (6 957±722) mm(3) significantly (all P<0.01); on the mouse backside without injection treatment, the tumor volumes of group MH1005 (5 952±607) and MH1006 (5 473±661) mm(3) were smaller than those of HSV-wt (6 785±1 063), MH1001 (6 774±808) and Mock (6 957±190) mm(3) significantly (all P<0.05); after 35 days of treatment, the mice survival rates of group MH1005 (100%) and MH1006 (100%) were higher than those of MH1001 (67%), HSV-wt (50%) and Mock (33%) significantly (all P<0.05). Conclusion: MH1005 and MH1006 can infect nerve tumor cells and replicate at high level, the viruses not only kill tumor cells directly but also induce immunological rejection to tumor, and prolong the survival of mice bearing tumor.
目的： 构建删除ICP47并携载人IL－12的重组HSV－1，并在体外培养细胞和荷瘤小鼠体内研究其溶瘤特性。 方法： 利用细菌人工染色体技术获得删除ICP47的重组HSV－1 MH1005及其携载人IL－12的重组HSV－1 MH1006。检测HSV－wt、MH1005和MH1006感染多种神经肿瘤细胞时的复制水平和抑瘤效果。在小鼠背部两侧皮下注射Neuro－2a细胞建立荷瘤小鼠模型，分别于0、3和6 d在一侧瘤内注射2×10(6) PFU HSV－wt、MH1001(删除IR的重组HSV－1)、MH1005、MH1006和病毒储液(Mock)，观察肿瘤大小和小鼠生存时间。 结果： MH1005、MH1006和HSV－wt在293FT细胞中的复制能力差异均无统计学意义(均P>0.05)；重组HSV－1在G422和Neuro－2a细胞中的复制能力高于SK－N－SH细胞；重组HSV－1可显著抑杀神经肿瘤细胞。荷瘤小鼠治疗15 d时，HSV－wt、MH1001、MH1005和MH1006治疗组病毒注射侧肿瘤体积依次为(6 267±484)、(5 730±1 071)、(4 537±538)和(4 150±476) mm(3)，显著<Mock组肿瘤体积(6 957±722) mm(3)(P<0.01)；未注射侧肿瘤中，MH1005[(5 952±607) mm(3)]和MH1006[(5 473±661) mm(3)]治疗组肿瘤体积显著<HSV－wt组[(6 785±1 063) mm(3)]、MH1001[(6 774±808) mm(3)]和Mock组[(6 957±190) mm(3)](均P<0.05)；小鼠治疗35 d时MH1005(100%)和MH1006组(100%)生存率显著高于MH1001组(67%)、HSV－wt治疗组(50%)和Mock组(33%)(均P<0.05)。 结论： MH1005和MH1006可感染神经肿瘤细胞并高效复制，其直接抑杀肿瘤细胞的同时还可诱导小鼠对肿瘤细胞的免疫排斥，并延长荷瘤小鼠生存期。.
Keywords: Glioma; Herpesvirus 1, human; Interleukin-12; Oncolytic virotherapy.